Patient Leaflet Updated 24-May-2021 | Glenmark Pharmaceuticals Europe Ltd
Olanzapine Glenmark Europe
Olanzapine Glenmark Europe 5 mg orodispersible tablets
Olanzapine Glenmark Europe 10 mg orodispersible tablets
Olanzapine Glenmark Europe 15 mg orodispersible tablets
Olanzapine Glenmark Europe 20 mg orodispersible tablets
Olanzapine
1. What Olanzapine Glenmark Europe is and what it is used for
2. What you need to know before you take Olanzapine Glenmark Europe
3. How to take Olanzapine Glenmark Europe
4. Possible side effects
5. How to store Olanzapine Glenmark Europe
6. Contents of the pack and other information
Olanzapine Glenmark Europe contains the active substance olanzapine. Olanzapine Glenmark Europe belongs to a group of medicines called antipsychotics.
Olanzapine Glenmark Europe is used to treat the following conditions:
Olanzapine Glenmark Europe has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.
Talk to your doctor or pharmacist before you take Olanzapine Glenmark Europe
If you suffer from any of the following illnesses tell your doctor as soon as possible:
If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or “mini” stroke.
As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.
Olanzapine Glenmark Europe is not for patients who are under 18 years.
Only take other medicines while you are on Olanzapine Glenmark Europe if your doctor tells you that you can. You might feel drowsy if Olanzapine Glenmark Europe is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Tell your doctor if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor if you are taking:
Do not drink any alcohol if you have been given Olanzapine Glenmark Europe as together with alcohol it may make you feel drowsy.
If you are pregnant or breast feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not be given this medicine when breast-feeding, as small amounts of Olanzapine Glenmark Europe can pass into breast milk.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark Europe in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.
There is a risk of feeling drowsy when you are given Olanzapine Glenmark Europe. If this happens do not drive or operate any tools or machines. Tell your doctor.
Olanzapine Glenmark Europe contains a source of phenylalanine. This may be harmful for people with phenylketonuria.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will tell you how many Olanzapine Glenmark Europe orodispersible tablets to take and how long you should continue to take them. The daily dose of Olanzapine Glenmark Europe is between 5 mg and 20 mg. Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark Europe unless your doctor tells you to.
You should take your Olanzapine Glenmark Europe orodispersible tablets once a day following the advice of your doctor. Try to take your tablets at the same time each day. It does not matter whether you take them with or without food. Olanzapine Glenmark Europe orodispersible tablets are for oral use. Put the tablet in your mouth. It will dissolve directly in your mouth, so that it can be easily swallowed. You can also place the tablet in a full glass or cup of water or other suitable beverage (orange juice, apple juice, milk or coffee) and stir. Drink it straightaway.
Patients who have taken more Olanzapine Glenmark Europe than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. Contact your doctor or hospital straight away if you experience any of the above symptoms. Show the doctor your pack of tablets.
Take your tablets as soon as you remember. Do not take two doses in one day.
Do not stop taking your tablets just because you feel better. It is important that you carry on taking Olanzapine Glenmark Europe for as long as your doctor tells you.
If you suddenly stop taking Olanzapine Glenmark Europe, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you to reduce the dose gradually before stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately if you have:
Very common side effects (may affect more than 1 in 10 people) include:
Common side effects (may affect up to 1 in 10 people) include:
Uncommon side effects (may affect up to 1 in 100 people) include:
Rare side effects (may affect up to 1 in 1000 people) include:
Very rare side effects (may affect up to 1 in 10,000) include:
While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking. Some fatal cases have been reported in this particular group of patients.
In patients with Parkinson’s disease Olanzapine Glenmark Europe may worsen the symptoms
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of sight and reach and of children
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Store below 30°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
Olanzapine Glenmark Europe 5mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ‘B’ debossed on one side.
Olanzapine Glenmark Europe 10 mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL’ debossed on one side and ‘D’ debossed on other side.
Olanzapine Glenmark Europe 15 mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL’ debossed on one side and ‘E’ debossed on other side.
Olanzapine Glenmark Europe 20 mg:
yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL’ debossed on one side and ‘F’ debossed on other side.
Olanzapine Glenmark Europe 5 mg, 10 mg, 15 mg and 20 mg are available in aluminium foil blisters of 28, 56, and 70 orodispersible tablets
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
This leaflet was last revised in 04/2021.
Building 2, Croxley Park, Watford, WD18 8YA
+44 (0)1923 251137
www.glenmarkpharma.com
+44 (0)1923 202 950
0800 458 0383
+44 (0)1923 202 950